Matt Holian serves as the Global Co-Chair of DLA Piper’s Life Sciences Sector. Matt’s practice focuses on litigation, regulatory and enforcement challenges facing pharmaceutical and medical device companies. His litigation practice primarily involves serving as national counsel in complex, multi-jurisdictional product liability suits, for which DLA Piper’s Product Liability and Mass Tort practice group has been recognized by Legal 500 as Tier 1 since 2014 and by Chambers as Band 2 or Band 3 since 2015. In those cases, Matt defends his clients from start to finish, beginning with litigation risk assessments before medications are approved and continuing through pretrial discovery, bellwether trials and, ultimately, resolution. Matt also has litigated cases involving environmental contamination, the False Claims Act, consumer fraud, and commercial disputes relating to licensing agreements.
WHAT CLIENTS SAY
"Matt is very responsive, smart, and attuned to our goals. He was especially great at helping us in an MDL class action."
"Matt is really smart. He offers practical advice because he understands the company and our goals."
"He takes the time and effort to make sure he absolutely knows the specific needs of a matter."
MY CLIENT PHILOSOPHY
"Clients want trusted advisors who can provide thoughtful, practical, and well-informed judgment about how to approach problems in a way that shows we understand their business priorities. But clients aren’t just entities; they are people with their own interests, and I try to understand and account for that too. Because being a truly trusted advisor also requires being a friend who cares about the success of the clients we serve, both as an enterprise and as a collection of people."
– Matthew Holian
ALL-STAR BIOGRAPHY
Matt Holian serves as the Global Co-Chair of DLA Piper’s Life Sciences Sector. Matt’s practice focuses on litigation, regulatory and enforcement challenges facing pharmaceutical and medical device companies. His litigation practice primarily involves serving as national counsel in complex, multi-jurisdictional product liability suits, for which DLA Piper’s Product Liability and Mass Tort practice group has been recognized by Legal 500 as Tier 1 since 2014 and by Chambers as Band 2 or Band 3 since 2015. In those cases, Matt defends his clients from start to finish, beginning with litigation risk assessments before medications are approved and continuing through pretrial discovery, bellwether trials and, ultimately, resolution. Matt also has litigated cases involving environmental contamination, the False Claims Act, consumer fraud, and commercial disputes relating to licensing agreements.
ALL-STAR BIOGRAPHY
Matt Holian serves as the Global Co-Chair of DLA Piper’s Life Sciences Sector. Matt’s practice focuses on litigation, regulatory and enforcement challenges facing pharmaceutical and medical device companies. His litigation practice primarily involves serving as national counsel in complex, multi-jurisdictional product liability suits, for which DLA Piper’s Product Liability and Mass Tort practice group has been recognized by Legal 500 as Tier 1 since 2014 and by Chambers as Band 2 or Band 3 since 2015. In those cases, Matt defends his clients from start to finish, beginning with litigation risk assessments before medications are approved and continuing through pretrial discovery, bellwether trials and, ultimately, resolution. Matt also has litigated cases involving environmental contamination, the False Claims Act, consumer fraud, and commercial disputes relating to licensing agreements.